Lung cancer - Biomira delays lung cancer drug trial

Biomira delays lung cancer drug trial
Pharmaceutical Business Review - 15 hours ago stability issue during the manufacturing process, Canadian company Biomira, has delayed the start of a planned phase III study for its lung cancer drug, BLP25